Core Insights - Upstream Bio announced positive results from the Phase 2 VALIANT trial for verekitug, showing significant reductions in asthma exacerbation rates and improvements in lung function [2][3][4] Efficacy and Safety - Verekitug demonstrated a 56% reduction in annualized asthma exacerbation rate (AAER) at a dose of 100 mg every 12 weeks and a 39% reduction at 400 mg every 24 weeks compared to placebo [3] - Improvements in lung function were observed, with a placebo-adjusted increase in forced expiratory volume in one second (FEV1) of 122 mL for the 100 mg q12w group and 139 mL for the 400 mg q24w group [4] - The drug also significantly suppressed exhaled nitric oxide (FeNO), with reductions of 20.4 ppb and 26.3 ppb for the respective dosing regimens [4] Patient Enrollment and Future Trials - Over 90% of eligible patients from the VALIANT trial have transitioned to the Phase 2 VALOUR long-term extension study [8] - Upstream Bio plans to advance verekitug into Phase 3 trials for severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) following regulatory interactions [6][9] Company Overview - Upstream Bio is focused on developing treatments for inflammatory diseases, particularly severe respiratory disorders, and is advancing verekitug as a unique antagonist targeting the TSLP receptor [19][12] - The company has conducted multiple Phase 2 trials for verekitug, including studies for chronic obstructive pulmonary disease (COPD) and CRSwNP, and is committed to addressing unmet needs in severe asthma treatment [18][19]

LAS VEGAS, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Premier Development & Investment, Inc. (OTC: PDIV) (“The Company” or “Premier”) confirms the distribution of a very detailed update early next week and upon all (and other undisclosed) items as detailed in our Press Releases dated December 16 and 19, 2025. A link, for ease of reference: https://www.otcmarkets.com/stock/PDIV/news/Premier-Development--Investment-Inc-Updates-on-Social-Media-and-Investor-Relations?id=504543. Further link for ease of reference: https: ...

Press Release Eviden trains the Belgian Army’s Land Forces on the Scorpion Combat Information System (SICS) Bourg-Léopold, Belgique – February 10, 2026 – Eviden, the Atos Group product brand leading in cybersecurity products, mission-critical systems and vision AI, today announces, that it took part in the inauguration of the first national training platform for the SCORPION Combat Information System (SICS) by the Belgian Defense in Bourg-Léopold, Belgium. The SICS is the digital nervous system of the new ...

100,000-metre drilling program underway, targeted for completion by year-endDrilling and trenching immediately north of the high-grade OMZ resource delivers significant oxide intercepts, including: 66m @ 0.9 g/t Au (OKND 30) and 6m @ 4.1 g/t Au (trench ONCH 3)New discovery at the “Sands” target area delivers near-surface, oxidized drill intercepts, including: 24m @ 2.5 g/t Au (NWOD 70), 5m @ 4.8 g/t Au (NWOD 69), and 21.4 m @ 0.5 g/t Au (NWOD 75) TORONTO, Feb. 11, 2026 (GLOBE NEWSWIRE) -- G2 Goldfields Inc. ...

CLEAR To Announce Fourth Quarter and Full Year 2025 Financial Results On February 25, 2026 [Accessibility Statement] Skip NavigationNEW YORK, Feb. 11, 2026 /PRNewswire/ -- Clear Secure, Inc. (NYSE: YOU), the secure identity platform, today announced that it will report financial results for the fourth quarter and full year ending December 31, 2025 at approximately 6:00 a.m. ET on Wednesday, February 25, 2025. At 8:00 a.m. ET, results will be discussed via live webcast and teleconference.Investors and analys ...

BOSTON, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Bioxytran, Inc. (OTCQB: BIXT) today announced positive clinical results from its recently completed Phase 2 randomized, double-blind, placebo-controlled, dose-optimization trial evaluating ProLectin-M in subjects with laboratory-confirmed acute viral infection. The Bioxyytran Trial reports complete elimination of viral load in 100% of patients at day 7 versus placebo (p=.001). The completed Phase 2 clinical study was a randomized, double-blind, placebo-controlled, ...

Youdao (NYSE:DAO) Q4 2025 Earnings call February 11, 2026 05:00 AM ET Speaker2Good day and welcome to Youdao's fourth quarter 2025 and full year earnings conference call. Today's conference is being recorded. At this time, I would like to turn the conference over to Mr. Jeffrey Wang, Investor Relations Director of Youdao. Please go ahead.Speaker1Thank you, Operator. Please note the discussion today will contain forward-looking statements related to the future performance of the company, which are intended t ...

HOUSTON, TX / ACCESS Newswire / February 11, 2026 / National Energy Services Reunited Corp. ("NESR" or the "Company") (Nasdaq:NESR) an international, industry-leading provider of integrated energy services in the Middle East and North Africa ("MENA") region, today announced that it will release its financial results for the fourth quarter of 2025 on Tuesday, February 17th, 2026. A conference call is scheduled for 8:00 AM ET on February 17th, 2026, to discuss the financial results. ...

SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will report its fourth quarter and full year 2025 financial results on Thursday, February 26, 2026 before the financial markets open. Following the release of the financials, the Company will host a live webcast with management at 8:00 a.m. ET. The live webcast of this event can be accessed from the investors section of the Company's website at https://ir.beonemedicin ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部份內容而產生或因倚賴該等內容 而引致之任何損失承擔任何責任 。 兗礦能源集團股份有限公司 YANKUANG ENERGY GROUP COMPANY LIMITED* （在中華人民共和國註冊成立的股份有限公司） （股份代碼：01171） 海外監管公告 於其他市場披露的資料 本公告乃根據《香港聯合交易所有限公司證券上市規則》第13.10B條的披露義務而作出。 茲 載 列 兗 礦 能 源 集 團 股 份 有 限 公 司 日 期 為 2026 年 2 月 11 日 ， 在 上 海 證 券 交 易 所 網 站 （www.sse.com.cn）和公司網站（www.ykenergy.com）刊登下列公告，僅供參閱。 1.《兗礦能源集團股份有限公司關於調整限制性股票回購價格的公告》； 2.《兗礦能源集團股份有限公司關於回購註銷部分激勵對象已獲授但尚未解除限售的限制性股票 的公告》； 3.《兗礦能源集團股份有限公司關於2021年A股限制性股票激勵計畫第三個解除限售期解除限售 條件達 ...